Becton Dickinson and Co. (NYSE:BDX) on Monday reported first-quarter 2026 adjusted earnings of $2.91 per share, beating the consensus of $2.81.
The company reported sales of $5.25 billion, slightly above the consensus of $5.15 billion.
Revenues increased 1.6% as reported, and 0.4% adjusted FXN.
Segment Earnings Overview
Medical essentials segment sales were up 0.6% (-0.6% FXN) to $1.595 billion.
- Medication Delivery Solutions’ performance reflects expected order timing dynamics and VoBP in China, partially offset by continued share gains in U.S. Vascular Access Management.
- Specimen Management sales of $468 million reflect expected order timing dynamics and VoBP in China, partially offset by solid growth in the BD Vacutainer portfolio in the U.S.
Connected Care segment generated sales of $1.13 billion, up 5.5% (+4.7% FXN).
- In Medication Management Solutions, solid pharmacy automation growth was driven by BD Rowa and stronger Infusion performance driven by order timing and higher infusion-set utilization.
- Advanced Patient Monitoring witnessed strong volume growth across the portfolio, led by Smart Recovery, HemoSphere Alta Monitor, and continued adoption of Acumen IQ Sensor.
BioPharma Systems’ sales of $429 million were up 2.7% (+1% FXN), driven by double-digit growth in Biologics, partially offset by lower market demand for vaccine products.
Interventional …